Karyopharm announces new interim phase 2 selinexor data in myelofibrosis selected for oral presentation at the american society of hematology 2021 annual meeting and exposition

Newton, mass., nov. 4, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an abstract detailing new data from a phase 2 study evaluating selinexor, a first-in-class, oral selective inhibitor of nuclear export (sine) compound, in patients with myelofibrosis (mf) previously treated with jak inhibition has been selected for an oral presentation at the upcoming american society of hematology (ash) 2021 annual meeting and exposition in atlanta, ga on december 11-14, 2021.
KPTI Ratings Summary
KPTI Quant Ranking